Monitor for additional equity grants or insider activity, especially given the activist context; while this filing is routine, a pattern of equity inducements could signal talent retention challenges or dilutive practices.
SYRE drugs
SYRE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $48.98entry
- T+1 · 7mo ago +4.53%α +4.47% · $51.20
- T+5 · 7mo ago +29.18%α +25.04% · $63.27
- T+20 · 7mo ago +41.14%α +32.16% · $69.13
- T+60 · 5mo ago +81.48%α +68.01% · $88.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spyre Therapeutics granted stock options to purchase 70,200 shares to five non-executive employees as inducement awards under its 2018 Equity Inducement Plan. The options have a 10-year term, an exercise price of $48.90, and vest over four years, with one-fourth vesting on the first anniversary and monthly thereafter, subject to continued service.
Key Facts
- Spyre granted stock options for 70,200 shares to five non-executive employees.
- Options were granted under Nasdaq Listing Rule 5635(c)(4) as inducement awards.
- Exercise price is $48.90, equal to the closing price on April 1, 2026.
- Options have a 10-year term and vest 25% on first anniversary, then 1/48th monthly over next 36 months.
- Grants were material to employment acceptances.
Financial Impact
Minimal near-term financial impact; total potential dilution of 70,200 shares (~0.19% of $3.7B market cap at $48.90).
Risk Factors
- Potential for incremental shareholder dilution if future inducement grants scale significantly.
- Activist scrutiny may increase if governance or compensation practices are perceived as excessive.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268133 |
Track record
36 reports on SYRE
8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers